Возможности излечения больных со злокачественными новообразованиями торакоабдоминальной локализации при сопутствующей ишемической болезни сердца

According to statistical reports, cardiovascular diseases and cancer are most common causes of death. In spite of an improving trend in cancer care 1-year survival of patients with concomitant thoracoabdominal cancer and ishemic heart disease is 8 + 5% only. Efficient therapy for ischemic heart disease and definitive surgery for cancer improve by several times outcomes of surgical treatment. Atotal of 500 patients aged 43 to 83 years (78.7% of men and 21.3% of women) with thoracoabdominal cancer and ischemic heart disease were managed at the N. N. Blokhin RCRC during 2002 through 2008. Definitive surgical treatment for cancer and therapy for ischemic heart disease were given to patients with lung cancer (n = 239), lung metastases (n = 27), esophageal (n = 79), gastric (n = 108) and colonic (n = 47) cancers. Cases with locally advanced tumors were 50.1%. Preoperative therapy included β-adrenoblockers, statins or fibrates, antithrombotics. Treatment for heart failure, arrhythmia and severe coronary disease was given as indicated. Freguency of these complications of ischemic heart disease was 20.6, 17.0 and 8.8% respectively. The treatment was supplemented with rational psychotherapy as the principal correction modality for anxietydepression syndrome manifested by a various degree in one third to half of the patients; in 16.4% of cases this state reguired special psychologist's support. As a result of definitive surgical and therapeutic treatment for concomitant thoracoabdominal cancer and ischemc heart disease 214 (64.8%) patients survived one year, the rate being at least eight-fold as high as the respective life expectancy. Note that beside the 214 one-year survivors, another 187 of the 500 patients receiving treatment were lost to or continue under follow-up for less than 1 year. A total of 34.0% of study patients are surviving one year following definitive surgery and therapeutic treatment free from evidence of cancer or heart disease, i. e. may be considered cured from the diseases in guestion for a one-year period.